Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

Blood

Volumn 120, Issue 23, 2012, Pages 4621-4634

  Lapalombella, Rosa ^a   Sun, Qingxiang ^b   Williams, Katie ^a   Tangeman, Larissa ^a   Jha, Shruti ^a   Zhong, Yiming ^a   Goettl, Virginia ^a   Mahoney, Emilia ^a   Berglund, Caroline ^a   Gupta, Sneha ^a   Farmer, Alicia ^b   Mani, Rajeswaran ^a   Johnson, Amy J ^a,c   Lucas, David ^a,c   Mo, Xiaokui ^c   Daelemans, Dirk ^d   Sandanayaka, Vincent ^e   Shechter, Sharon ^e   McCauley, Dilara ^e   Shacham, Sharon ^e   Kauffman, Michael ^e   Chook, Yuh Min ^b   Byrd, John C ^a,c   more..

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^e Karyopharm Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ALEMTUZUMAB; ANTILEUKEMIC AGENT; CASPASE 3; CD19 ANTIGEN; CYSTEINE; EXPORTIN 1; FLUDARABINE; I KAPPA B ALPHA; INTERLEUKIN 10; INTERLEUKIN 6; KPT 185; KPT 251; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OFATUMUMAB; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BRG 1; PROTEIN MCL 1; PROTEIN P50; PROTEIN P53; SELECTIVE INHIBITOR OF NUCLEAR EXPORT; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR FKHRL1; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL KILLING; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; COVALENT BOND; CRYSTAL STRUCTURE; CYTOPLASM; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SCID MOUSE; STRUCTURE ACTIVITY RELATION; WEIGHT REDUCTION;

EID: 84870502798     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-429506     Document Type: Article

References (52)

1. Xu D, Farmer A, Chook YM. Recognition of nuclear targeting signals by Karyopherin-beta proteins. Curr Opin Struct Biol. 2010;20(6):782-790.
2. Güttler T, Gorlich D. Ran-dependent nuclear export mediators: a structural perspective. EMBO J. 2011;30(17):3457-3474.
3. Dong X, Biswas A, Suel KE, et al. Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature. 2009;458:1136-1141.
4. Yao Y, Dong Y, Lin F, et al. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep. 2009;21(1):229-235.
5. Monecke T, Guttler T, Neumann P, Dickmanns A, Gorlich D, Ficner R. Crystal structure of the nuclear export receptor CRM1 in complex with Snurportin1 and RanGTP. Science. 2009;324(5930):1087-1091.
6. Güttler T, Madl T, Neumann P, et al. NES consensus redefined by structures of PKI-type and Revtype nuclear export signals bound to CRM1. Nat Struct Mol Biol. 2010;17(11):1367-1376.
7. Koyama M, Matsuura Y. An allosteric mechanism to displace nuclear export cargo from CRM1 and RanGTP by RanBP1. EMBO J. 2010;29(12):2002-2013.
8. Kutay U, Hetzer MW. Reorganization of the nuclear envelope during open mitosis. Curr Opin Cell Biol. 2008;20(6):669-677.
9. Turner JG, Sullivan DM. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem. 2008;15(26):2648-2655.
10. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol. 2012;83(8):1021-1032.
11. Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery. 2009; 65(1):153-159, discussion 159-160.
12. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254-266. (Pubitemid 40110814)
13. Falini B, Gionfriddo I, Cecchetti F, Ballanti S, Pettirossi V, Martelli MP. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy? Blood Rev. 2011;25(6):247-254.
14. Colombo E, Bonetti P, Lazzerini Denchi E, et al. Nucleophosmin is required for DNA integrity and p19Arf protein stability. Mol Cell Biol. 2005;25(20):8874-8886. (Pubitemid 41429079)
15. Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer. 2004;4(2):106-117. (Pubitemid 38198739)
16. Laín S, Midgley C, Sparks A, Lane EB, Lane DP. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp Cell Res. 1999;248(2):457-472. (Pubitemid 29394805)
17. Laín S, Xirodimas D, Lane DP. Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function. Exp Cell Res. 1999;253(2):315-324. (Pubitemid 30003092)
18. Mutka SC, Yang WQ, Dong SD, et al. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res. 2009;69(2):510-517.
19. Roberts BJ, Hamelehle KL, Sebolt JS, Leopold WR. In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721). Cancer Chemother Pharmacol. 1986;16(2):95-101. (Pubitemid 16155974)
20. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer. 1996;74(4):648-649. (Pubitemid 26279064)
21. Shao C, Lu C, Chen L, Koty PP, Cobos E, Gao W. p53-Dependent anticancer effects of leptomycin B on lung adenocarcinoma. Cancer Chemother Pharmacol. 2011;67(6):1369-1380.
22. Van Neck T, Pannecouque C, Vanstreels E, Stevens M, Dehaen W, Daelemans D. Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action. Bioorg Med Chem. 2008;16(21):9487-9497.
23. Chook YM, Blobel G. Structure of the nuclear transport complex karyopherin-beta2-Ran x GppNHp. Nature. 1999;399(6733):230-237. (Pubitemid 29246446)
24. Lapalombella R, Andritsos L, Liu Q, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinasedependent pathway. Blood. 2010;115(13):2619-2629.
25. Lapalombella R, Yu B, Triantafillou G, et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood. 2008;112(13):5180-5189.
26. Herman SE, Lapalombella R, Gordon AL, et al. The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood. 2011;117(16):4323-4327.
27. Johnson AJ, Lucas DM, Muthusamy N, et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood. 2006;108(4):1334-1338. (Pubitemid 44232033)
28. Paraskeva E, Izaurralde E, Bischoff FR, et al. CRM1-mediated recycling of snurportin 1 to the cytoplasm. J Cell Biol. 1999;145(2):255-264. (Pubitemid 29198299)
29. Wolff B, Sanglier JJ, Wang Y. Leptomycin B is an inhibitor of nuclear export: inhibition of nucleocytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem Biol. 1997;4(2):139-147. (Pubitemid 27161752)
30. Daelemans D, Costes SV, Lockett S, Pavlakis GN. Kinetic and molecular analysis of nuclear export factor CRM1 association with its cargo in vivo. Mol Cell Biol. 2005;25(2):728-739. (Pubitemid 40096593)
31. van der Watt PJ, Maske CP, Hendricks DT, et al. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer. 2009;124(8):1829-1840.
32. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10(1):37-50.
33. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood. 2008;111(2):846-855.
34. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol. 2000;164(4):2200-2206. (Pubitemid 30108780)
35. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:481-488.
36. Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood. 2005;106(2):408-418. (Pubitemid 40981231)
37. Nishio M, Endo T, Tsukada N, et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood. 2005;106(3):1012- 1020. (Pubitemid 41076448)
38. Kurtova AV, Balakrishnan K, Chen R, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009;114(20):4441-4450.
39. Roecklein BA, Torok-Storb B. Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood. 1995;85(4):997-1005.
40. Lucas DM, Alinari L, West DA, et al. The novel deacetylase inhibitor AR-42 demonstrates preclinical activity in B-cell malignancies in vitro and in vivo. PLoS One. 2010;5(6):e10941.
41. Xu D, Grishin NV, Chook YM. NESdb: a database of NES-containing CRM1 cargos. Mol Biol Cell. 2012;23(18):3673-3676.
42. Turner JG, Marchion DC, Dawson JL, et al. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res. 2009;69(17):6899-6905.
43. Takenaka Y, Fukumori T, Yoshii T, et al. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol. 2004;24(10):4395-4406. (Pubitemid 41071009)
44. Noske A, Weichert W, Niesporek S, et al. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer. 2008;112(8):1733-1743. (Pubitemid 351536833)
45. Daelemans D, Afonina E, Nilsson J, et al. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci U S A. 2002;99(22):14440-14445. (Pubitemid 35257690)
46. Sakakibara K, Saito N, Sato T, et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood. 2011;118(14):3922-3931.
47. Hussain SR, Cheney CM, Johnson AJ, et al. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res. 2007;13(7):2144-2150. (Pubitemid 46649884)
48. Bannerji R, Kitada S, Flinn IW, et al. Apoptoticregulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol. 2003;21(8):1466- 1471. (Pubitemid 46594097)
49. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood. 1998;91(9):3379-3389. (Pubitemid 28193890)
50. Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood. 2002;100(1):194-199. (Pubitemid 35177447)
51. Michels J, O'Neill JW, Dallman CL, et al. Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene. 2004;23(28):4818-4827. (Pubitemid 38932154)
52. Etchin J, Kentsis A, Sanda T, et al. KPT-SINE, a potent, small molecule inhibitor of CRM1-dependent nuclear-cytoplasmic shuttling, with potent activity against T-ALL and AML [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):2622.